Breast cancer: Endomagnetics receives IDE approval to initiate US trials

[News]

Cancer healthcare company Endomagnetics has announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to initiate a...

More... (http://www.medicalnewstoday.com/releases/286266.php)